EU parliament could kill global anti-counterfeit agreement by summer
This article was originally published in Scrip
Executive Summary
The controversial Anti-Counterfeiting Trade Agreement, ACTA, aimed at tackling intellectual property rights violations across all sectors, could be dead in the water by the summer if the European Parliament follows the recommendations of its ACTA rapporteur, David Martin. Mr Martin will recommend that the parliament rejects the agreement, which would mean it could not be ratified in the EU. This could, in turn, influence whether countries outside the EU ratify it, say commentators.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.